Journal: Advanced Healthcare Materials

Article Title: An Animal‐Free Patient‐Derived Tissue‐Mimetic Biochip Model of the Human Synovial Membrane for Human‐Relevant Osteoarthritis Research

doi: 10.1002/adhm.202404799

Figure Lengend Snippet: (A,B) Impact of ascorbic acid supplementation (+S; 100 µ m ) on the condensation dynamics of synovial biochip organoids (n = 3) shown in (A) as comparison between day 3 and day 14 post‐seeding as well as images (B) of day 14 biochip‐cultured constructs. (C) Comparison of gene expression of COL1A1, COL3A1, PRG4, CDH11, VEGFA, IL6, CXCL8, MMP1, MMP3, MMP13 and ADAMTS5 for primary OA patient‐derived synovial fibroblasts maintained with non‐animal protocols in the presence and absence of 100 µ m ascorbic acid after 14 days of maturation (n = 3‐4), data are expressed as mean with 95% CI with 2 ‐way ANOVA (A) and Kruskal‐Wallis analysis (C). The given sample number (n) always refers to biological replicates/different patient samples.

Article Snippet: Before using primary antibodies were prepared in 10% goat serum for anti‐human Yap1 (1:50, recombinant anti‐rabbit, Abcam, ab205270) and in 10% horse serum for CDH11 (1:200, anti‐mouse, R & D Systems, MAB 1790), collagen type I (1:1000, anti‐goat, Southern Biotech, 1310‐01) and collagen type III (1:250, anti‐mouse, Abcam, ab6310) were incubated overnight in a staining chamber at 4 °C.

Techniques: Comparison, Cell Culture, Construct, Gene Expression, Derivative Assay

Journal: Advanced Healthcare Materials

Article Title: An Animal‐Free Patient‐Derived Tissue‐Mimetic Biochip Model of the Human Synovial Membrane for Human‐Relevant Osteoarthritis Research

doi: 10.1002/adhm.202404799

Figure Lengend Snippet: (A) Gene expression analysis of COL1A1, COL3A1, and PRG4 mRNA for primary OA patient‐derived non‐animal 3D biochip organoids after 14 days of maturation (n = 10, data are shown as mean with 95% CI) using the optimized culture conditions of 1% hPL and 0.1 mM ascorbic acid. (B) Histological evaluation of the regional location of collagen type I (COL1), collagen type III (COL3), cadherin‐11 (CDH11) as well as sulfated glycosaminoglycans (Methylene blue). Primary antibodies included recombinant anti‐human cadherin‐11 (1:50), collagen type I (1:50), and collagen type III (1:50). (C) Baseline secretion levels of OA hallmark proteins on days 3 and 14 of human OA synovial organoids during on‐chip culture (n = 6). Data are shown as mean with 95% CI with Wilcoxon matched‐pairs signed rank test. The given sample number (n) always refers to biological replicates/different patient samples.

Article Snippet: Before using primary antibodies were prepared in 10% goat serum for anti‐human Yap1 (1:50, recombinant anti‐rabbit, Abcam, ab205270) and in 10% horse serum for CDH11 (1:200, anti‐mouse, R & D Systems, MAB 1790), collagen type I (1:1000, anti‐goat, Southern Biotech, 1310‐01) and collagen type III (1:250, anti‐mouse, Abcam, ab6310) were incubated overnight in a staining chamber at 4 °C.

Techniques: Gene Expression, Derivative Assay, Recombinant